These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34302778)

  • 21. [Prion Properties of Alpha-Synuclein].
    Schwarzman AL; Senkevich KA; Emelyanov AK; Pchelina SN
    Mol Biol (Mosk); 2019; 53(3):380-387. PubMed ID: 31184602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Modelling synucleinopathies in genetically modified animals--successes and failures].
    Ninkina NN; Ustiugov AA; Bukhman VL
    Mol Biol (Mosk); 2008; 42(5):840-55. PubMed ID: 18988533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
    Miraglia F; Betti L; Palego L; Giannaccini G
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic approaches in Parkinson's disease and related disorders.
    Valera E; Masliah E
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):346-352. PubMed ID: 26749150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [REM Sleep Behavior Disorder and α-synucleinopathy].
    Miyamoto T; Numahata K; Ishido H; Miyamoto M
    Brain Nerve; 2020 Feb; 72(2):107-117. PubMed ID: 32036336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
    Peelaerts W; Baekelandt V
    J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebral potential biomarkers discovery and metabolic pathways analysis of α-synucleinopathies and the dual effects of Acanthopanax senticosus Harms on central nervous system through metabolomics analysis.
    Zhang SN; Li XZ; Lu F; Liu SM
    J Ethnopharmacol; 2015 Apr; 163():264-72. PubMed ID: 25660332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When Do α-Synucleinopathies Start? An Epidemiological Timeline: A Review.
    Savica R; Boeve BF; Mielke MM
    JAMA Neurol; 2018 Apr; 75(4):503-509. PubMed ID: 29459985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
    Merchant KM; Cedarbaum JM; Brundin P; Dave KD; Eberling J; Espay AJ; Hutten SJ; Javidnia M; Luthman J; Maetzler W; Menalled L; Reimer AN; Stoessl AJ; Weiner DM;
    J Parkinsons Dis; 2019; 9(1):31-61. PubMed ID: 30400107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathological biochemistry of alpha-synucleinopathy.
    Iwatsubo T
    Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery.
    Arotcarena ML; Teil M; Dehay B
    Cells; 2019 Jun; 8(6):. PubMed ID: 31181865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
    Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
    Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
    Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
    BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays.
    Candelise N; Schmitz M; Thüne K; Cramm M; Rabano A; Zafar S; Stoops E; Vanderstichele H; Villar-Pique A; Llorens F; Zerr I
    Transl Neurodegener; 2020; 9():5. PubMed ID: 31988747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synucleinopathies: Where we are and where we need to go.
    Brás IC; Dominguez-Meijide A; Gerhardt E; Koss D; Lázaro DF; Santos PI; Vasili E; Xylaki M; Outeiro TF
    J Neurochem; 2020 May; 153(4):433-454. PubMed ID: 31957016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies.
    Herrmann Y; Bujnicki T; Zafiu C; Kulawik A; Kühbach K; Peters L; Fabig J; Willbold J; Bannach O; Willbold D
    Clin Chim Acta; 2017 Mar; 466():152-159. PubMed ID: 28088342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.